Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Tomoko Inoue
CEO
tomoko.inoue@jocavio.jp

Message the company or request a 1:1 meeting here

JOCAVIO Co. Ltd. was founded in 2021 by Drs. Tomoko and Hiroyuki Inoue together with seasoned industry experts in 2021 with a vision to provide “Hope for the Irreplaceable Lives of Cancer Patients”. JOCAVIO’s core expertise is genetic manipulation of vaccinia virus and the unique coating technology that enable repeated systemic administration of virus vectors. Moreover, we utilize a promising nanobody technology that allows multi-epitope binding for cancer specific tropism. Our primary focus is a novel oncolytic virus that provides not only robust efficacy with multiple targets but also possesses a “kill switch” that inhibits virus replication in case of excess activity. Utilizing our expertise on vaccinia virus, we have a project on SARS-Cov-2 vaccine that would be effective regardless of different variants. This project is an expedited project in needs of effective vaccines and will enter FIH in 3Q 2023 and we expect to complete P2 in 2024. Similarly, some early pipelines in consideration include vaccines that are effective for Zika and Dengue fever. We are looking for investors to help us in seed finance to support FIH in 2024-2025. Also we are keen on a strategic partnership with companies who are interested in co-development of our vaccine projects in APAC countries.

Pitch Video

Slide Deck